We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Abbott Diagnostics

  Gold Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App





Abbott Reissued FDA Emergency Use Authorization for ID Now COVID-19 Test

By HospiMedica International staff writers
Posted on 21 Sep 2020
Print article
Image: Abbott ID Now (Photo courtesy of Abbott)
Image: Abbott ID Now (Photo courtesy of Abbott)
Abbott (Lake Forest, IL, USA) has been reissued Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the company's ID Now COVID-19 test.

The revisions to the previous EUA letter of authorization include a revised intended use to indicate that testing is for specimens collected “from individuals who are suspected of COVID-19 by their health care provider within the first seven days of the onset of symptoms;” clarify that testing is authorized for laboratories certified under CLIA and meet the requirements to perform high, moderate, or waived complexity tests; and clarify that testing facilities within the United States and its territories are required to report all results to the appropriate public health authorities.

The reissuance has also revised the labeling to update specimen transport and storage recommendations and to include results of the FDA SARS-CoV-2 Reference Panel Testing; updated conditions of authorization to reflect consistency with more recent authorizations; and revised the health care provider and patient fact sheets to reflect the intended use updates and language more consistent with recent authorizations.



Print article
Radcal
M.I ONE Co., Ltd

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.